View More Recent Stories
-
COMPASS Pathways plc (CMPS) Announces Publication of Results from COMP004 Study on COMP360 Psilocybin
-
H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS)
-
Compass Pathways (CMPS) PT Lowered to $15 at Canaccord Genuity
-
COMPASS Pathways plc (CMPS) Reports In-Line Q4 EPS
-
Stifel Starts Compass Pathways (CMPS) at Buy
-
Compass Pathways (CMPS) PT Lowered to $45 at H.C. Wainwright
-
Cantor Fitzgerald provides update on Biotechnology stocks
-
Compass Pathways (CMPS) PT Lowered to $9 at Rodman & Renshaw
-
COMPASS Pathways plc (CMPS) Appoints Steve Levine as Chief Patient Officer
-
COMPASS Pathways plc (CMPS) prices 24M ADS at $5.796
-
COMPASS Pathways plc (CMPS) to Join NASDAQ Biotechnology Index (NBI)
-
Compass Pathways (CMPS) PT Lowered to $23 at Canaccord Genuity
-
Compass Pathways (CMPS) PT Lowered to $60 at H.C. Wainwright
-
Compass Pathways (CMPS) PT Lowered to $18 at RBC Capital
-
COMPASS Pathways plc (CMPS) Tops Q3 EPS by 1c
-
TD Cowen Reiterates Buy Rating on Compass Pathways (CMPS)
-
Compass Pathways (CMPS) PT Lowered to $48 at Canaccord Genuity
-
COMPASS Pathways plc (CMPS) Misses Q2 EPS by 3c
-
RBC Capital Starts Compass Pathways (CMPS) at Outperform
-
RBC Capital Starts Compass Pathways (CMPS) at Outperform
-
COMPASS Pathways plc (CMPS) Appoints Lori Englebert as Chief Commercial Officer

